Docoh
Loading...

35 results

Filter options loading...
Top filers
Top filing types
Recent filing years
10-Q
2021 Q2
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
trials and disruptions in the supply chain for raw materials used in clinical trial work. Such delays could materially impact our business in future
10-Q
2021 Q1
PCSA Processa Pharmaceuticals Inc
13 May 21
Quarterly report
4:30pm
such as ours, including possible delays in clinical trials and disruptions in the supply chain for raw materials used in clinical trial work
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
operations and result in lost sales. Additionally, we rely on third parties to supply the raw materials needed to manufacture our potential products. Any … for raw materials used in clinical trial work. Such delays could materially impact our business in future periods. Furthermore, the spread of COVID-19
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
of a contract manufacturer could be disruptive to our operations and result in lost sales. Additionally, we rely on third parties to supply the raw materials needed
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Sep 20
IPO registration (amended)
4:06pm
to our operations and result in lost sales. Additionally, we rely on third parties to supply the raw materials needed to manufacture our potential
S-1/A
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
in lost sales. Additionally, we rely on third parties to supply the raw materials needed to manufacture our potential products. Any reliance on suppliers
S-1/A
PCSA Processa Pharmaceuticals Inc
17 Jul 20
IPO registration (amended)
5:25pm
on third parties to supply the raw materials needed to manufacture our potential products. Any reliance on suppliers may involve several risks, including
10-K
2019 FY
PCSA Processa Pharmaceuticals Inc
5 Mar 20
Annual report
7:00pm
or the loss of a contract manufacturer could be disruptive to our operations and result in lost sales. Additionally, we rely on third parties to supply the rawmaterials needed to manufacture our potential products. Any reliance on suppliers may involve several risks, including a potential inability to obtain
S-1
PCSA Processa Pharmaceuticals Inc
13 Dec 19
IPO registration
5:32pm
on third parties to supply the raw materials needed to manufacture our potential products. Any reliance on suppliers may involve several risks, including
10-K/A
2018 FY
PCSA Processa Pharmaceuticals Inc
5 Apr 19
Annual report (amended)
9:40pm
to supply the raw materials needed to manufacture our potential products. Any reliance on suppliers may involve several risks, including a potential
10-K
2018 FY
PCSA Processa Pharmaceuticals Inc
28 Mar 19
Annual report
5:25pm
to supply the raw materials needed to manufacture our potential products. Any reliance on suppliers may involve several risks, including a potential
424B3
PCSA Processa Pharmaceuticals Inc
9 Nov 18
Prospectus supplement
5:04pm
sales. Additionally, we rely on third parties to supply the raw materials needed to manufacture our potential products. Any reliance on suppliers may
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Oct 18
IPO registration (amended)
4:19pm
to our operations and result in lost sales. Additionally, we rely on third parties to supply the raw materials needed to manufacture our potential
S-1/A
PCSA Processa Pharmaceuticals Inc
9 Oct 18
IPO registration (amended)
5:32pm
rely on third parties to supply the raw materials needed to manufacture our potential products. Any reliance on suppliers may involve several risks
S-1/A
PCSA Processa Pharmaceuticals Inc
13 Sep 18
IPO registration (amended)
8:00pm
of a contract manufacturer could be disruptive to our operations and result in lost sales. Additionally, we rely on third parties to supply the rawmaterials needed to manufacture our potential products. Any reliance on suppliers may involve several risks, including a potential inability to obtain
S-1
PCSA Processa Pharmaceuticals Inc
29 Jul 18
IPO registration
8:00pm
be disruptive to our operations and result in lost sales. Additionally, we rely on third parties to supply the raw materials needed to manufacture our
10-K/A
2017 FY
PCSA Processa Pharmaceuticals Inc
16 Apr 18
Annual report (amended)
8:00pm
on third parties to supply the raw materials needed to manufacture our potential products. Any reliance on suppliers may involve several risks, including
10-K
2017 FY
PCSA Processa Pharmaceuticals Inc
15 Apr 18
Annual report
8:00pm
manufacturer could be disruptive to our operations and result in lost sales. Additionally, we rely on third parties to supply the raw materials needed
8-K
EX-99.1
PCSA Processa Pharmaceuticals Inc
25 Sep 14
Regulation FD Disclosure
8:00pm
demand for sustainability continues to increase, HEATWURX is committed to providing superior solutions that reduce consumption of raw materials by re
8-K
EX-99.1
PCSA Processa Pharmaceuticals Inc
6 Aug 14
Regulation FD Disclosure
8:00pm
consumption of raw materials by re-using existing asphalt, extending the life of asphalt pavements, and decreasing the costs of recurring repairs